Drug Discovery

Human Genetics in Drug Target Prioritization

Published 2026-08-22 · Updated 2026-08-22

Answer in brief

For Human Genetics in Drug Target Prioritization, speed comes from a precise decision and a fast falsifier. State how much causal and safety weight human genetic evidence should receive, evaluate competing routes with variant-to-gene mapping, effect direction, phenotype, ancestry, pleiotropy, dosage, and replication, and attempt to test colocalization or fine-mapping assumptions with alternative models and data. The output is an inspectable next-direction recommendation, not a substitute for laboratory, clinical, engineering, or regulatory validation.

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

how much causal and safety weight human genetic evidence should receive

Why the problem is difficult

The article-specific identification challenge is whether the question “how much causal and safety weight human genetic evidence should receive” can be resolved using variant-to-gene mapping, effect direction, phenotype, ancestry, pleiotropy, dosage, and replication, rather than merely restated in new language.

A falsifier-first workflow

  • Define the decision precisely: how much causal and safety weight human genetic evidence should receive.
  • Build a source and data ledger around variant-to-gene mapping, effect direction, phenotype, ancestry, pleiotropy, dosage, and replication.
  • Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
  • Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
  • Run the lowest-cost discriminating challenge: test colocalization or fine-mapping assumptions with alternative models and data.
  • Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

  • Decision impact: would the result materially change the choice about how much causal and safety weight human genetic evidence should receive?
  • Evidence fit: does the available evidence—variant-to-gene mapping, effect direction, phenotype, ancestry, pleiotropy, dosage, and replication—directly address the decision rather than merely correlate with it?
  • Discrimination: does the preferred route predict an outcome a credible alternative does not?
  • Robustness: does the ranking survive the challenge “test colocalization or fine-mapping assumptions with alternative models and data”?
  • Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

variant-to-gene mapping, effect direction, phenotype, ancestry, pleiotropy, dosage, and replication

Counterevidence

For this decision, a result from “test colocalization or fine-mapping assumptions with alternative models and data” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about how much causal and safety weight human genetic evidence should receive or exposes why the available evidence cannot resolve it.

Fastest falsifier

test colocalization or fine-mapping assumptions with alternative models and data

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “test colocalization or fine-mapping assumptions with alternative models and data” without an independently supported alternative mechanism.

Evidence ceiling

Genetic perturbation across a lifetime is not equivalent to pharmacological intervention.

Sources and starting points

  • Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
  • ChEMBL — Curated bioactivity information for compounds, assays, and targets.
  • ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
  • PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
  • Europe PMC — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
  • PubChem — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

  1. Drug Target Prioritization: A Falsifier-First Framework
  2. Target Identification vs Target Validation in Drug Discovery
  3. What Counts as Evidence for Drug Target Validation?
  4. Map the Translational Gap Before Advancing a Drug Program

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “Human Genetics in Drug Target Prioritization” help make?
It supports a bounded decision about how much causal and safety weight human genetic evidence should receive. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.
What is the fastest useful test?
test colocalization or fine-mapping assumptions with alternative models and data
Can computation validate the final scientific claim?
No. Genetic perturbation across a lifetime is not equivalent to pharmacological intervention. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.
When should the project stop or reframe?
Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.